ENTA - Enanta files patent infringement lawsuit against Pfizer over Paxlovid

According to a Lawsuit filed on Tuesday in U.S. District Court for the District of Massachusetts, Pfizer's blockbuster COVID drug Paxlovid violates biotechnology company Enanta Pharmaceuticals's (NASDAQ:ENTA) patent for its COVID drug still in development. The suit is seeking damages in the manufacture, use and sale of Paxlovid. Enanta said it received a patent earlier this month based on a July 2020 patent application "describing coronavirus protease inhibitors invented by Enanta scientists." Paxlovid has been used to treat patients suffering from Covid-19. Enanta said it "does not intend to seek an injunction or take other action in this litigation that would impede the production, sale or distribution of Paxlovid." The company said it "seeks fair compensation for Pfizer's use of a coronavirus 3CL protease inhibitor claimed" in its patent.

For further details see:

Enanta files patent infringement lawsuit against Pfizer over Paxlovid